Severe skin and soft tisue infections and associated critical illness

Current Infectious Disease Reports

Volumn 8, Issue 5, 2006, Pages 375-383

  Vinh, Donald C ^b   Embil, John M ^a  

^a HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; FUSIDIC ACID; IMMUNOGLOBULIN; LINEZOLID; MACROLIDE; METICILLIN; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXACILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TELAVANCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL PNEUMONIA; CELLULITIS; CLINICAL FEATURE; CLINICAL TRIAL; CRITICAL ILLNESS; DISEASE ASSOCIATION; DRUG MECHANISM; EMPIRICISM; HOST PATHOGEN INTERACTION; HUMAN; INFECTION RISK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL COLONIZATION; MUSCLE NECROSIS; NECROTIZING FASCIITIS; OUTCOMES RESEARCH; PYODERMA; REVIEW; RISK ASSESSMENT; SEPTIC SHOCK; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; TOXIC SHOCK SYNDROME; TREATMENT PLANNING;

EID: 33748997366     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-006-0048-y     Document Type: Review

References (56)

1. Ellis Simonsen SM, van Orman ER, Hatch BE, et al.: Cellulitis incidence in a defined population. Epidemiol Infect 2006, 134:293-299.
2. Vinh DC, Embil JM: Rapidly progressive soft tissue infections. Lancet Infect Dis 2005, 5:501-513.
3. Angus DC, Linde-Zwirble WT, Lidicker J, et al.: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
4. Rennie RP, Jones RN, Mutnick AH, et al.: Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003, 45:287-293.
5. Sader HS, Jones RN, Silva JB, et al.: Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. Diagn Microbiol Infect Dis 2002, 44:281-288.
6. Jones ME, Karlowsky JA, Draghi DC, et al.: Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003, 22:406-419.
7. Cohen J, Cristofaro P, Carlet J, et al.: New method of classifying infections in critically ill patients. Crit Care Med 2004, 32:1510-1526.
8. Stevens DL: Streptococcal toxic shock syndrome associated with necrotizing fasciitis. Annu Rev Med 2000, 51:271-288.
9. Davies HD, McGeer A, Schwartz B, et al.: Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med 1996, 335:547-554.
10. Aronoff DM, Bloch KC: Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine (Baltimore) 2003, 82:225-235.
11. Bisno AL, Stevens DL: Streptococcal infections of skin and soft tissues. N Engl J Med 1996, 334:240-245.
12. Nichols RL, Florman S: Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect Dis 2001, 33(Suppl 2):S84-93.
13. Simonart T, Simonart JM, Derdelinckx I, et al.: Value of standard laboratory tests for the early recognition of group A beta-hemolytic streptococcal necrotizing fasciitis. Clin Infect Dis 2001, 32:E9-12.
14. Kaul R, McGeer A, Low DE, et al.: Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am J Med 1997, 103:18-24.
15. Muller MP, Low DE, Green KA, et al.: Clinical and epidemiologic features of group A streptococcal pneumonia in Ontario, Canada. Arch Intern Med 2003, 163:467-472.
16. Centers for Disease Control and Prevention: Case definitions for infectious conditions under public health surveillance: Streptococcal toxic shock syndrome. MMWR 1997, 46:33-34.
17. Currie BJ: Group A streptococcal infections of the skin: molecular advances but limited therapeutic progress. Curr Opin Infect Dis 2006, 19:132-138.
18. Herwald H, Cramer H, Morgelin M, et al.: M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 2004, 116:367-379.
19. Banks DJ, Beres SB, Musser JM: The fundamental contribution of phages to GAS evolution, genome diversification and strain emergence. Trends Microbiol 2002, 10:515-521.
20. Beres SB, Sylva GL, Sturdevant DE, et al.: Genome-wide molecular dissection of serotype M3 group A Streptococcus strains causing two epidemics of invasive infections. Proc Natl Acad Sci USA 2004, 101:11833-11838.
21. Sun H, Ringdahl U, Homeister JW, et al.: Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 2004, 305:1283-1286.
22. Walker MJ, McArthur JD, McKay F, et al.: Is plasminogen deployed as a Streptococcus pyogenes virulence factor? Trends Microbiol 2005, 13:308-313.
23. Thulin P, Johansson L, Low DE, et al.: Viable group A streptococci in macrophages during acute soft tissue infection. PLoS Med 2006, 3:e53.
24. Chhatwal GS, McMillan DJ: Uncovering the mysteries of invasive streptococcal diseases. Trends Mol Med 2005, 11:152-155.
25. Hidalgo-Grass C, Dan-Goor M, Maly A, et al.: Effect of a bacterial pheromone peptide on host chemokine degradation in group A streptococcal necrotizing soft-tissue infections. Lancet 2004, 363:696-703.
26. Kotb M, Norrby-Teglund A, McGeer A, et al.: An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002, 8:1398-1404.
27. Stevens DL, Madaras-Kelly KJ, Richards DM: In vitro anti-microbial effects of various combinations of penicillin and clindamycin against four strains of Streptococcus pyogenes. Antimicrob Agents Chemother 1998, 42:1266-1268.
28. Zimbelman J, Palmer A, Todd J: Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999, 18:1096-1100.
29. Mulla ZD, Leaverton PE, Wiersma ST: Invasive group A streptococcal infections in Florida. South Med J 2003, 96:968-973.
30. Freeman AF, Shulman ST: Macrolide resistance in group A Streptococcus. Pediatr Infect Dis J 2002, 21:1158-1160.
31. De Azavedo JC, Yeung RH, Bast DJ, et al.: Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada. Antimicrob Agents Chemother 1999, 43:2144-2147.
32. Richter SS, Heilmann KP, Beekmann SE, et al.: Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 2005, 41:599-608.
33. Ikebe T, Hirasawa K, Suzuki R, et al.: Antimicrobial susceptibility survey of Streptococcus pyogenes isolated in Japan from patients with severe invasive group A streptococcal infections. Antimicrob Agents Chemother 2005, 49:788-790.
34. Uh Y, Jang IH, Hwang GY, et al.: Antimicrobial susceptibility patterns and macrolide resistance genes of beta-hemolytic streptococci in Korea. Antimicrob Agents Chemother 2004, 48:2716-2718.
35. Darenberg J, Ihendyane N, Sjolin J, et al.: Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003, 37:333-340.
36. Kaul R, McGeer A, Norrby-Teglund A, et al.: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999, 28:800-807.
37. Norrby-Teglund A, Muller MP, Mcgeer A, et al.: Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 2005, 37:166-172.
38. Lamothe F, D'Amico P, Ghosn P, et al.: Clinical usefulness of intravenous human immunoglobulins in invasive group A Streptococcal infections: case report and review. Clin Infect Dis 1995, 21:1469-1470.
39. Daneman N, McGeer A, Low DE, et al.: Hospital-acquired invasive group A streptococcal infections in Ontario, Canada, 1992-2000. Clin Infect Dis 2005, 41:334-342.
40. Smith A, Lamagni TL, Oliver I, et al.: Invasive group A streptococcal disease: should close contacts routinely receive antibiotic prophylaxis? Lancet Infect Dis 2005, 5:494-500.
41. Simor AE, Ofner-Agostini M, Paton S, et al.: Clinical and epidemiologic features of methicillin-resistant Staphylococcus aureus in elderly hospitalized patients. Infect Control Hosp Epidemiol 2005, 26:838-841.
42. NNIS System: National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003, 31:481-498.
43. Kowalski TJ, Berbari EF, Osmon DR: Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphylococcus aureus infections. Mayo Clin Proc 2005, 80:1201-1207.
44. Cosgrove SE, Sakoulas G, Perencevich EN, et al.: Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003, 36:53-59.
45. Lee MC, Rios AM, Aten MF, et al.: Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004, 23:123-127.
46. Miller LG, Perdreau-Remington F, Rieg G, et al.: Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005, 352:1445-1453.
47. Peleg AY, Munckhof WJ, Kleinschmidt SL, et al.: Life-threatening community-acquired methicillin-resistant Staphylococcus aureus infection in Australia. Eur J Clin Microbiol Infect Dis 2005, 24:384-387.
48. Adem PV, Montgomery CP, Husain AN, et al.: Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005, 353:1245-1251.
49. Fridkin SK, Hageman JC, Morrison M, et al.: Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005, 352:1436-1444.
50. Ellis MW, Lewis JS 2nd: Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr Opin Infect Dis 2005, 18:496-501.
51. Markowitz N, Quinn EL, Saravolatz LD: Trimethoprimsulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992, 117:390-398.
52. Ruhe JJ, Monson T, Bradsher RW, et al.: Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005, 40:1429-1434.
53. Lewis JS 2nd, Jorgensen JH: Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis 2005, 40:280-285.
54. Drinkovic D, Fuller ER, Shore KP, et al.: Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrobial Chemother 2001, 48:315-316.
55. Panagea S, Perry JD, Gould FK: Should clindamycin be used as treatment of patients with infections caused by erythromycin-resistant staphylococci? J Antimicrobial Chemother 1999, 44:581-582.
56. Rao GG: Should clindamycin be used in treatment of patients with infections caused by erythromycin-resistant staphylococci? J Antimicrobial Chemother 2000, 45:715.